OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher?

OmniAb, Inc. (NASDAQ:OABI) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has gained more than 38% over the past 6 months and around 74% since the release of its fiscal Q1 2026 earnings and business update.

​The company reported earnings on May 7, showing significant improvement and prompting an upgrade to its full-year guidance. During the quarter, the revenue surged from $4.2 million to $14.4 million compared to the same quarter last year. Management attributed the increase to  be largely driven by milestone payments from partner programs advancing into later-stage clinical trials.

​Notably, the cost came down as research and development costs dropped from $12.6 million to $9.6 million, and general & administrative costs fell from $7.9 million to $6.6 million. Moreover, the net loss narrowed from $18.2 million in Q1 2025 to $7.7 million in Q1 2026. Management also highlighted  OmniUltra and the xPloration partner access program as recent additions to its portfolio.

​As a result of this strong performance, OmniAb, Inc. (NASDAQ:OABI) raised the full-year guidance and now expects revenue to be in the range of $28 million – $33 million, up from the previous range of $25 million – $30 million.

OmniAb Inc. (NASDAQ:OABI) provides licenses to pharmaceutical and biotech companies for discovery research technology around various parts of the world. To find the best antibodies and other target-binding proteins for partners’ drug development efforts, the company’s technology platform creates and screens diverse antibody repertoires. Animal-based technologies are also offered by the company.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.